LUPIN - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.3
| Stock Code | LUPIN | Market Cap | 1,04,889 Cr. | Current Price | 2,295 ₹ | High / Low | 2,378 ₹ |
| Stock P/E | 19.0 | Book Value | 596 ₹ | Dividend Yield | 0.52 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,232 ₹ | DMA 200 | 2,095 ₹ |
| Chg in FII Hold | 1.00 % | Chg in DII Hold | -0.98 % | PAT Qtr | 1,241 Cr. | PAT Prev Qtr | 869 Cr. |
| RSI | 55.2 | MACD | 28.5 | Volume | 11,90,656 | Avg Vol 1Wk | 8,29,049 |
| Low price | 1,774 ₹ | High price | 2,378 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 86.3 % | Qtr Profit Var | 18.6 % | EPS | 120 ₹ | Industry PE | 27.6 |
📊 Analysis: Lupin shows strong momentum for intraday trading today. RSI at 55.2 indicates healthy bullish strength without being overbought. MACD is positive (28.5), confirming upward momentum. Current price (2,295 ₹) is trading above both 50 DMA (2,232 ₹) and 200 DMA (2,095 ₹), showing strong short-term and medium-term support. Volume is significantly higher than the 1-week average, indicating strong participation and conviction in price action.
💡 Optimal Buy Price: Around 2,285–2,295 ₹ if intraday support holds.
🎯 Profit Exit Levels: 2,320 ₹ (first target), 2,350 ₹ (second target if momentum continues).
⚠️ Stop-Loss: 2,270 ₹ to protect against downside risk.
📌 If Already Holding: Consider exiting near 2,320–2,350 ₹ if momentum indicators show exhaustion. If price falls below 2,270 ₹ with volume confirmation, exit to avoid deeper losses.
✅ Positive
- Quarterly PAT growth (1,241 Cr. vs 869 Cr.).
- EPS at 120 ₹ supports strong earnings visibility.
- ROCE (21.9%) and ROE (17.8%) indicate solid capital efficiency.
- PEG ratio at 0.11 suggests undervaluation relative to growth.
- Price trading above both 50 DMA and 200 DMA, confirming bullish trend.
- Debt-to-equity ratio at 0.04, nearly debt-free.
⚠️ Limitation
- DII holdings decreased (-0.98%), showing reduced domestic confidence.
- High volatility near 52-week highs (86.3% index).
- Sector valuation risk as industry PE is 27.6 vs Lupin’s 19.0.
📉 Company Negative News
- DII stake reduction indicates cautious domestic sentiment.
- High volatility may trigger sharp intraday swings.
📈 Company Positive News
- Quarterly profit growth of 18.6% shows operational improvement.
- FII holdings increased (+1.00%), showing strong foreign investor confidence.
- Dividend yield at 0.52% adds income stability.
🏭 Industry
- Pharma sector trading at PE ~27.6, Lupin is undervalued with P/E of 19.0.
- Sector demand remains defensive, benefiting from healthcare expansion and global pharma exports.
🔎 Conclusion
Lupin is a strong intraday candidate today with bullish momentum, high volume, and favorable technical setup. A buy near 2,285–2,295 ₹ with targets at 2,320 ₹ and 2,350 ₹ offers opportunity, but traders should maintain a strict stop-loss at 2,270 ₹ due to volatility risk. Best suited for momentum-based intraday trades with potential swing opportunities given strong fundamentals and undervaluation relative to peers.
Would you like me to also prepare a peer benchmarking overlay with other pharma leaders (like Sun Pharma, Cipla, Dr. Reddy’s) so you can compare Lupin’s intraday strength against sector peers?